Alice Melão,  —

Cerevance has initiated a Phase 2 clinical trial to evaluate the safety and efficacy of its oral investigational therapy CVN424 for treating Parkinson’s disease motor symptoms. CVN424 is small molecule that can penetrate the brain and modulate the activity of specific nerve cells in the striatum…

Patients who undergo deep brain stimulation to treat Parkinson’s disease may lose their ability to swim, even if their motor symptoms improve after the treatment or if they were formerly proficient swimmers, a collection of nine case studies has found. The study, “Beware of deep water after…

Startup company Jesse Medical and researchers from the Royal Melbourne Institute of Technology (RMIT) have agreed to collaborate on the further development and commercialization of new software to enable early detection and improved monitoring of Parkinson’s disease. The screening technology analyzes the results of seven specific drawing and…

A new application for Android tablets, called SleepFit, may help to monitor the daily progression and response to treatment of motor symptoms associated with Parkinson’s disease, according to a study. The application was evaluated in the study “A New Prospective, Home-Based Monitoring of Motor Symptoms in Parkinson’s…

The impact of climate change and environmental risk factors on brain health was spotlighted at this year’s World Congress of Neurology, a gathering of scientists and clinicians to discuss the latest advances and future developments in neurology. The recent XXIV World Congress of Neurology in Dubai, United Arab Emirates,…

People with type 2 diabetes being treated with thiazolidinedione compounds, such as Actos (pioglitazone) and Avandia (rosiglitazone), may be at lower risk of Parkinson’s disease, a pilot study suggests. However, more work is needed to confirm a potential to prevent Parkinson’s in an at-risk patient population. The…

Military veterans with post-traumatic stress disorder (PTSD) or who experienced a traumatic brain injury have more than double the risk of a rare sleep disorder — called rapid eye movement (REM) sleep behavior disorder — previously reported as a risk factor for Parkinson’s disease, a study finds. Researchers at…

A detailed analysis of alpha-synuclein — a key protein involved in Parkinson’s — revealed how variants of this protein change over time, allowing researchers to identify the initial stages of protein aggregation involved in early onset disease. These findings provide new insights into how genetic mutations — especially…

Cases of inherited Parkinson’s disease may be more frequent than previously reported, results from an online global survey suggest. The survey, which was conducted by members of The Michael J. Fox Foundation Global Genetic Parkinson’s Study Group (MJFF-GGPSG), also revealed the willingness of investigators to share clinical information on…

Yumanity Therapeutics announced the start of a Phase 1 clinical study in healthy volunteers that will assess the safety and tolerability of YTX-7739, a potential disease-modifying therapy for Parkinson’s disease. Trial results are expected to be announced in the first quarter of 2020. YTX-7739 is designed to cross the blood-brain-barrier…